LOGO

You are here: 

  • Home

 



 

  • Clavis Pharma raises USD 20 million

    Clavis Pharma ASA has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the “Private Placement”).

    >> Read more26.06.09

  • The Bioeconomy to 2030: DESIGNING A POLICY AGENDA

    The study considers the role biotechnology could play in addressing what are considered the most serious challenges to world economies and societies over the next decades.

    >> Read more18.06.09

  • Algeta demonstrates potential

    Algeta ASA announces that a series of scientific papers demonstrating the targeted and localized anticancer potential of the alpha-emitter thorium-227 (227Th) linked to trastuzumab (Herceptin) and to rituximab (Rituxan) will be presented at the forthcoming 56th annual Society for Nuclear Medicine 2009 meeting (Toronto, Canada; 13-17 June).

    >> Read more10.06.09

  • Biotec Pharmacon on track for marketing

    The biopharmaceutical company Biotec Pharmacon has completed the patient inclusion in both its phase III studies with SBG for treatment of diabetic foot ulcer. Study results are expected to be ready by the end of the year, and Biotec Pharmacon is on track to file for marketing authorization with SBG for treatment of diabetic foot ulcer in Europe mid-2010.

    >> Read more17.05.09

  • Significant progress in Algeta

    Algeta has progressed significantly during 2009 with several important events occurring during the first quarter, according to results for the first quarter.

    >> Read more17.05.09

  • New CEO in Navamedic ASA

    Olof Milveden is appointed new CEO of Navamedic ASA.

    >> Read more05.05.09

  • World Innovation Summit i Barcelona

     EU har annonsert 2009 som "The Year of Creativity and Innovation". Spania (Barcelona) har tatt et initiativ ved å lansere møteplassen (mellom investorer og entreprenører) "HIT Barcelona - World Innovation Summit" fra 17.6 til 19.6.2009 i Barcelona.

    >> Read more24.04.09

  • Metvix and Aktilite approved by Health Canada

    Photocure ASA has announced that Metvix® in combination with Aktilite® CL128, the LED based red light technology device, has been approved by Health Canada for the treatment of actinic keratosis and superficial basal cell carcinoma.

    >> Read more21.04.09

  • Photocure wins patent case in USA

    The US Eastern District Court of Virginia has now granted summary judgment in Photocure's favour, in a patent case concerning the extension of its US patent covering the FDA-approved drug product Metvixia(TM).

    >> Read more02.04.09

  • Consortium led by PCI Biotech becomes a "Eurostar"

    A PCI Biotech-led consortium ranked 3rd of more than 300 Europan projects and has been awarded € 1.1 million grant from the EU Eurostars Programme.

    >> Read more31.03.09

Showing from 51 to 60 of total 90 articles

Events

    >> All events

 

 


 

Norwegian Bioindustry Association

Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98